Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Arcturus Therapeutics First Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Following the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Tuesday, May 9, 2023.

I would now like to turn the conference over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. ahead. go Please

Neda Safarzadeh

and Good will quarter operator. Today’s welcome Arcturus session our our to will CFO. well. Sassine, Thank Pad as in Dr. financial afternoon, for update first Chivukula, President Payne, Joseph XXXX led and call. and and Therapeutics Andy be our COO you, CSO by and CEO; join pipeline call Q&A progress the

are call Private not provisions everyone begin, facts that to the regarding I matters XXXX. during made of Reform we statements that Before forward-looking of remind this historical Harbor are within Securities would statements Safe Act like the Litigation the

Forward-looking statements materially expressed or that They assumptions may known are cause statements. implied actual by from and those the and performance. differ involve unknown results, risks, to and guarantees not uncertainties, performance of achievements

filings on recent Please as today, in as issued the statement see XX-K forward-looking Form company’s and the our press release factors earlier the subsequent the with section most SEC. risk well disclaimer in

In statements represent specifically only statements to date or views addition, reflect information, any the update events are Arcturus obligation any future disclaims circumstances. forward-looking statements as such to made. of such our

Joe. I’ll that, with over to turn the And call now

Joseph Payne

to the good remarks most good advanced evening will I program. you, effective our is ARCT-XXX program. longer X all offer This highlighting Thank and against friends COVID-XX. COVID-XX on clinical Neda, has our afternoon my to East by to and lasting and potential the Coast. our begin protection vaccine ARCT-XXX Phase

as favorable immunization variants based primary Phase collaborator was to X – potential new was and application placebo-controlled of pleased a to Phase demonstrated support primary X safety preventing COVID-XX Meiji month met report endpoint its profile. study. a vaccine ARCT-XXX and period concern Study study submitted conducted of very that of a during of our conducted our I’m last on approval drug the multiple a

pleased with XX,XXX subjects and by being have results Phase ARCT-XXX expected conducted the interim ARCT-XXX to this X very Meiji and efficacy quarter. results. of against XXX is comparative they individuals conducted Pharma we’re was study booster COVID-XX approximately with study The of Seika assess approximately This a as later enrollment completed and

and to study of BioNTech non-inferiority bio is – the designed administered compared a safety Comirnaty evaluate as of and Pfizer to ARCT-XXX immunogenicity as and booster dose. This a

later expect We and product PMDA to data representing first analysis ARCT-XXX submitted registration later potentially year, company’s a the this booster of seek the be primary series to our interim to as and the this approval. quarter

novel our of Arcturus. could Such ARCT-XXX medicine significant the a technologies mRNA indicative Japanese approved for to opportunity commercial the a represent opportunity broader years. result therapeutics meaningful could over of milestone platform sales be coming in vaccines If for and

also well and whereby to product government. Meiji In remind collaboration agreement by an being ARCT-XXX you related entered Japan. Seqirus booster will Seika funded Meiji Meiji into X for will sales are that manufacturing responsible ARCT-XXX April, I Seika as with study, as Phase be and of the Japanese CSL Pharma the this in distribution the Japanese Pharma

competent with commercial partnered and We be are indeed experienced fortunate to partners.

fees the the we specified for specified million XXXX, runs April – payment advanced reservation manufacturing ARCT-XXX, $XX.X manufacturing the In related advanced of received The and is is manufacturing of well of payment which CSL. supply from substance for ARCT-XXX an includes as as and drug requirements.

is benefits is provide dose-related in a product features frozen safety lower. vaccines meaningful mRNA very The The lyophilized, shipping, important liquid conventional potential than different is dose liquid. bring it’s and chain. or not a much much supply and better storage, a These ways. ARCT and So

safety X offer will we backdrop, the the also variants franchise. time Phase data with COVID-XX. longer vaccine of protection neutralizing immunogenicity globe. only our and This broad ARCT-XXX share concern. on shown and able the to top potential against lasting And has capability but ARCT-XXX exciting indeed show not regulators multiple has continues effective, this for to is of an booster soon multiple across be to against

move our to designed address OTC urea thereby prevent medicine deficiency. neurological therapeutic cycle damage. for is ARCT-XXX. mRNA I’ll OTC and now that This in investigational to This candidate on activity crises restore and the on enzyme liver update is deficient cause metabolic the to

patients LUNAR an living is protein profile. that liberalize attribute restrictions could the the with of important for utilizes of our rapidly those a administered this which lead to ARCT-XXX today proprietary we and expect potentially condition. safety strict favorable face degraded, life delivery dietary technology, that quality improve ARCT-XXX technology lipids are OTC Arcturus’

data ongoing is adolescents in in the Phase and in a The adults year evaluated X study the on this later begun has and adults. in Europe. adolescents and a Phase with participants in Arcturus XX study Phase of study designed enroll Xb ARCT-XXX ARCT-XXX is Phase X multi-dose adults Phase subset and multiple two X in plans interim Enrollment deficiency X UK to study to up to patients, share being clinical in dose studies XXXX. OTC and a

on move Now, to I’ll ARCT-XXX.

been therapeutic delivery. for designed for our protein functional delivery inhaled fully CF that the Our with CFTR optimized RNA fibrosis express messenger in LUNAR cystic candidate of utilizing lungs to inhaled is lung technology that this individuals program has

of preclinical clinical animal and underlying a the CF mouse demonstrating a currently model. ARCT-XXX ferret and CFTR by wide to that of those provide protein approach approved CFTR The CFTR associated a functional benefit Our shown well and the knockout and clinical a with living ARCT-XXX the of of is in mRNA successful agnostic supported by channel could with as CFTR served mutations CF, in disease, of modulators. range model, and the delivery epithelium those encouraging expression are restoration different development across airway the including lung data, not result, species, the is

of development to as according current. administration In epithelial has as continues to restoration chloride expression to of from ARCT-XXX protein vitro patient plan. cells functional donors clinical robust also addition, bronchial CFTR advance CF in ARCT-XXX The demonstrated of well program

year. each that enrollment being today healthy study report completed successfully X the anticipate four doses to reporting in subjects including of XX the later pleased administration have we and results this a and safety protocol eight of Phase study working study and We’re amendment expansion we participants, with tolerability tested, with The Arcturus of support to CF allow patients and of is enrollment in to of and year. dosing the this on initiate inclusion CF, a the the data patients expects QX

now call pass to With the that, Andy. I’ll on

Andy Sassine

reference The earlier details year-over-year performance. of Thank XXXX and press the more analysis financial Form on XX-Q for first and and of everyone. financial good a also provides financial performance. you, for Joe, today statements issued sequential summary includes quarter the release afternoon, and our Please

We to by drug the Meiji the new are for see application to Japan happy progress the on in ARCT-XXX. PMDA submitting

to is an data by completed quality self and be the vaccine shortly it checked We for be submitted of dose. and will expect mRNA This Meiji platform. order first in to in NDA booster is amplifying a the once Arcturus as submission our seek booster instrumental registration validation vaccine the

sheet We we reservation specified steps non-recourse Principal substance in of the which obligations. from $XX interest of April we long-term debt the to Singapore for utilized in By manufacturing million of XXXX, as as received Unused for the CSL. fees ARCT-XXX of includes number booster and with $XX.X quarter runs loan payment balance payment an of $XX is eliminated requirements. ARCT-XXX, the took principal on vaccines and advanced advanced manufacturing in drug In related improve our million elimination positive $XX accrued repaying the additional The the manufacturing well a interest, this and million supply of million and loan.

Bank. off to we Additionally, our paid $XX debt Bridge million obligation

XXXX, XX, on quarter which have due XXXX. is from I our and March $XX second beginning current remains during sales the and of expected to we long-term to commercial from by no sales. assets cash of in assuming the XXXX am based happy accounts million any current milestones As report million, revenues to primarily be pipeline CSL, extended the of increased balance sheet debt or our product runway while our no receivable $XX collected to based

of our biotechnology arrangements of and I will partners. quick fees, consulting from related research XXXX. reservation of revenues fees, pharmaceutical now received the transfer fees technology from development sources payments provide primary were Arcturus and first and summary financial license for with quarter results and a collaborative

first the March million three for increase quarter related million in in is revenue was attributable compared to the XXXX. CSL, achieved with increase ended million revenue XXXX months revenues for in $X.X $XX.X XX, primarily XXXX. an with the The of an Total to milestones the three XX, ended months associated $XX.X agreement of March

an for sequential activities is $XX.X to the agreement increases the to for three and cost three extent in in compared million and XXXX. XX, the expense months on attributable XX, December three related with to supply months million increase expenses for manufacturing operating cystic fibrosis manufacturing ended months $XX.X programs with increases associated COVID in various in collaboration, costs trial CSL and programs. the lesser clinical increase a primarily startup OTC XXXX XX to was and our ended for CSL related Total the The March with March

of debt XXXX, of We net For months income gain shares extinguishment share XX, recorded per to or in Arcturus the ended and or in XXXX. $XX.X Singapore $XXX.X March diluted ended the XXXX. or share net months loan of million three ended month $XX.X a $XX compared diluted reported $X.XX million one-time XXXX three the March during net million three March months million per approximately $X.XX loss the $X.XX XX, income three diluted of with December the related per XX, on a XX, in

ended XXXX. interest net months Additionally, $X.X we the reported XX, million three March for income of

was compared on position $XXX.X XX, cash $XXX.X XX, to of March XXXX. million March Our million as XXXX

expect achieved from associated million we in related with the manufacturing XXXX April, $XX received $XX.X CSL million the CSL. in the of and milestones March ARCT-XXX supply the of we second earlier, mentioned we As collect to And quarter in quarter. to

milestones the remains believe strong financial near-term that and creating for resources multiple programs over to we next months. summary, needed therapeutic In achieve position vaccine value the the has on and company nine the a

call Joe. I will pass now back to the

Joseph Payne

Andy. Thanks,

progress advanced toward later having RNA year. and stages delivery to development potentially have of excellent continued We lunar later make first proprietary this messenger and product our our technologies clinical approval and

an this time exciting is So at Arcturus.

with of vaccines making is strong strategic CSL, mRNA is next commercialization focused and the progress. generation Our development collaboration which on

and providing influenza, are the forward in teams I mRNA and development Our the information and milestones look targeting generation and progress to upcoming those COVID commercialization about coming more vaccines, toward our next including of quarters. working

to we’d questions. that, like turn the to the operator over with time for So

Operator

gentlemen, from session. Sandler. Your Yasmeen and from question. question-and-answer Piper Ladies will Rahimi the is you. now Please first Thank question begin we [Operator your ask Instructions]

Yasmeen Rahimi

imminent? February, in my the that given booster I it know noted and Great. are the already data waiting Thank one like, first Like was the instead lot or a month just, Meiji of we fall me potentially ahead the you study comment asking expected really finished maybe that July? team allowing enrollment we the I data. are this in of I file then the questions. in really, will May again guess, what guess ask to is for our so like, quarter And for booster are much clients to you or for later rationale of we’re June or May, in is, still

that And if address could and then so two follow-up. you

Joseph Payne

Sure.

first So X procedures. undergoing that booster your quality presently Phase and immunogenicity informed safety the first question, to respect control us final data with analysis interim are Meiji and

question with all respect So a the to guidance the QC that should the clear this the to very close, be submitted PMDA And next we’re regulator. audited booster means data this latter filing to from strategy, your PMDA just adhering we’re quarter. on right,

So to not platform to the regimen. but booster, and respect approve only want we with itself filing the that primary vaccination the

as they was NDA what filed according guided. to the So such

Yasmeen Rahimi

Okay. of approval And that is think third figure then Japan. the a to to I how in quantify are lot investors trying question out our the

was which is vaccines? junction by out – jump the what we the purchased? what terms the could I many guess And of granted approval? regulatory doses will find at of be you you I how one, into queue. number And negotiate Japan purchasing guess back with with then how ARCT-XXX So question soon I’ll the will in timeframe authorities

Joseph Payne

Yes.

been size framing opportunity, dosed market have terms year. of the boosters the of and for approximately X distributed of million people to last think September understand In I it’s Japanese since that helpful XX mRNA

mRNA distributed have approximately XXX that’s Japan. XX in So shots days million booster and been approximately

and on So speculations you mathematical calculations base can that. your

Andy Sassine

conducted We market. by with respect with discussions respective information Meiji typically and soon orders happy as would be government that and to on available, we don’t partners Yas, have we And the as to that’ll comment, with disclose our be information CSL.

Yasmeen Rahimi

jump into I’ll team. queue. you thank Okay, the back

Operator

Stavropoulos Pete from The Cantor question. one next you. Thank a from Fitzgerald. is Please ask

Pete Stavropoulos

and taking Hello questions. Joe Thank for team. and Andy you my

have the vaccine on one ARCT-XXX. So question I

of hear the there or non-inferiority in to against about Wuhan be? variants any that margin evaluating we of Are must concern? immunogenicity it the study terms Meiji of from the may against study. only So you activity the details provide study data can the what expect Is strain show

Joseph Payne

Yes, evaluated study parameters. the we’re study respect The to as question. is can – the being thanks definitely I Maybe Pete variants with strain the for and original that Pad. to the Wuhan are of of statistical concern other part throw evaluating

Pad Chivukula

be Yes, by Thanks be sure. rate the the response non-inferior forward. to and going Hi, of statistical XX. X.XX. just and for they’re of this But but of going already going – to lot be threshold Again, negative all looking data the of be Meiji done is objective to for And Pad. analysis an a sharing they’re question. the analysis, lot that doing going is will a them CR then

Pete Stavropoulos

color milestones, the can And this those be and regards you thanks. Okay, if what you milestones? provide more would the do those – with balance year, drive expect what in any so, to CSL of

Andy Sassine

question, your as throughout as them, But to don’t them to Unfortunately, guidance year. as soon we development progress for give thanks have achieved market with the we Pete. milestones. earned report the No, respect specific and the will we we Yes.

Pete Stavropoulos

in will at and All ARCT-XXX, it’s you tolerability, populations. healthy evaluate the looking for right, One fully completed the in I any be will is healthy terms focus volunteers thanks, in of last volunteers. biomarkers patient cystic Andy. enrolled you X, response? fibrosis pharmacodynamic also safety but know and How Phase you question

Joseph Payne

sure. Sure,

to data the expect with respect any to don’t So healthy we volunteers, biomarker meaningful. be

the that delivery their levels example. CFTR All and of But the is patient subjects inhaled healthy lungs, healthy tolerability first lunar dosing. have have volunteers This volunteers of of in are feasibility population or already and we safety closely for technology. tracking or

is we’re different dose basically of happy four levels, and So to we’ve evaluated extension very which chair. report today time that an

biomarker imagine in period patients these for technology report can intend actual that proof-of-concept drug and patients more or inhaling some are provided sitting where of we’ve product. CF we’ve of trial meaningful protocol in to each we’re happy the You the can we potential and the enroll guidance some in today of And completed amend to cohorts people that eight biological patients data. And is add chair a time, the QX. we to ARCT-XXX a find

Pete Stavropoulos

any color on there give – that potentially could you what that Is you can what look at?

Joseph Payne

time Yes. There us for do will to be an appropriate that.

next timing will I think call once at detail specifically. more the patient we that CF be of and quarterly the enrollment

Pete Stavropoulos

right. my questions. taking Thanks for you. All Thank

Joseph Payne

Thanks, Pete.

Operator

your from The Please from next question. you. Thank is Seamus Securities. Fernandez Guggenheim ask one

Evan Wang

Two this Hi Seamus. for guys, is questions. Wang Evan on

continued And for booster and a First development follow-up Japan us. on variance? I guess, set the and on about how platform talk you future you terms in helps have thinking guys COVID, how can up monovalent about in primary the streamline and are Yes. development bivalent approval of or a I

Joseph Payne

is question. platforms a mRNA updates. Seamus to update no clock rapid generation correct for mRNA doubt future from speed respect Yes, that ability the benefit platform. next and with Arcturus And It thanks, is

speed So seasonal market. rapid realize this a benefits, now benefit from is we perpetual update becoming is more which vaccine and that clock and we ability COVID overstated that

a that’s our the also callous local with our Japan, manufacturing to in that I want manufacturing presence highlight capability too. of presence

in ARCT-XXX future in is only the Japan. quickly, not it right can that itself, it’s sets manufactured not efficiently So and set just be asset stage great updates a but for locally

Evan Wang

from there the really protocol CF, amended patients? Great. And to study you what I hopefully investors on expansion update look Was it looking the when just And potential Zealand? enabled marker include does CF XXXX update to at? healthy specific later a guess, the New Will what you’re expand like? data? plan CF that And volunteers? do patient Will from Thanks. or then on both volunteer

Joseph Payne

question want program, So the that Seamus? restate this to I set just questions, your focusing on of you’re correct? last CF

Evan Wang

Correct.

Joseph Payne

so we to modify Okay. we to modify include intend intend to patients. – definitely the CF definitely protocol Yes,

specific likely think specific on give So will to a that. respect next time the more timing call be with more the of a update to I appropriate

can sort in this of to of is any biomarker ARCT-XXX when terms for the to sort early of patients, we In or get as thinking proof-of-concept some provide strategic too guidance.

Evan Wang

Okay. Thanks.

Joseph Payne

Thanks.

Operator

one next Nochomovitz from The Please from Yigal you. is your Citi. Thank question. ask

Carly Kenselaar

Hi, team. Carly much is Thanks our This on for so for Yigal. questions. taking

should what’s data as we for potentially your one expectation how ARCT-XXX FDA guess will bivalent questions. had to vaccines the major mRNA prior Japan? First use far the guidelines than I CSL a on bivalent guess, Meiji’s of follow-up could rather be focused related leveraged be I given outside be updated of to related as assumed, of markets.

dynamic you be on have helpful. thoughts any Just would that

Joseph Payne

Yes. now not vaccines, of that on mRNA not agencies correct, here types United conventional the Hi. in been It’s mandated other for different yet platforms and data bivalency have have And mRNA, agencies for regulatory have shared X in with the mandated and technologies. providing you’re guidance the we U.S. correct they the regulatory other Phase but they’ve our States, bivalency booster

So our to we differently whether are the conventional FDA prepared established. more mRNA be different will treated significantly in yet consider to But is situation. either or be technology like

is provided Japan respect our technology Europe. our We’re ongoing to We’ve in technology. in and bivalent monovalent that updates aggressively advancing with activity milestones,

particular So Did we’re question, in expects. depending on your requests or regulatory either prepared Carly? agency I address situation, what a

Carly Kenselaar

vaccine agreement CSL talked seasonal part COVID with know that have follow well were covered was that, We even up I just be if related that a that’s cell or as yes, planning? your I CF flu might to combo, curious if as Yes, developing have you of program. bivalent about a And flu program very helpful. guess, a COVID under a the

Joseph Payne

the that combined In provided a can’t the of flu, a combined details product. haven’t interesting. collaboration, fascinating definitely it I and CSL that we to any potential implies a is product combined of is for license speak timing there’s there. respect COVID and But did the disclose guidance to product. with so we But Yea,

Carly Kenselaar

be us, I Any Okay. triggered question from that to market? Japan Got great. you far on was could just CSL give then advanced last would the to you you just million can manufacturing specifically runs that as it. related that, And from what the elaborate clarity disclosed, as there payment supply just guess, $XX.X

Joseph Payne

Sure.

to prepare is requires you have of and manufacturing the vaccine XXX reservation imagine, As you substance, fees manufacture in well related production utilized manufacturing the could drug which for to which of requirements. as as

So if in by opportunity certain you time, orders if you want certain to potential get sense. to that a prepare makes for need that

Unidentified Analyst

That’s for questions. Thank it. the Got Okay. helpful. taking you

Joseph Payne

[indiscernible] you, Thank

Operator

Thank you. Fargo Yanan The question. Zhu from Securities. your next ask one Wells is Please from

Yanan Zhu

Hi, thanks for taking our questions.

Meiji So the informed for by booster XXX, Thank seeing? you. be the data required decision regulators is by indication, might booster they that primary the data primary the and vaccine the submit Japan approving data the by vaccine to on

Joseph Payne

question. Good

You get helpful, they approved, platform approved for as it forward. do future technologies it’s and – subsequent but the the booster not primary approved very can more not is as the bivalent or primary monovalent to get to appreciate the to you prerequisite have mature updates or come

platform and for our CSL for needed. that sure Meiji why allows subsequent the updates vaccine to timelines teams in make was is it Arcturus also and approval the and that because included So of primary the as accelerated NDA wanted and this PMDA and

Yanan Zhu

what part submit And primary large dataset consuming the by decision large, vaccine to encouraged you with consuming the a the is right? for time on obviously was process made it’s saw the because whether – in very Right. like question actually data, booster data, then this

Joseph Payne

that that according data after we’ve your that can they allow that data We ongoing can study’s since has We February. only made – comment whether on Yes. to to comment own not. But been that, decisions can’t the since Meiji collecting wisdom. that, to we as been December speculate or you based

Yanan Zhu

that? whether from bivalent vaccine shed Thank clients color very monovalent this available Japan we on That’s market. it. whether And with XXX the – some Got Could in the about helpful. get could effectively question compete the you. you

Joseph Payne

XX mentioned this that, million since dosed I on boosters September I there’s call X. Japan already in that guess, mRNA and distributed Sure. been just

the amplifying orders So significant government there’s that comparison. this in generation definitely X Phase whether Japan technology to mRNA take question compete the purposes a self one can care market And as Japanese next answer and for heads vaccine booster of the up that mRNA in that’s Meiji future. through of of we’ll this as – let

Pad Chivukula

to yes. as is others Hi, technology duration. add I’ll and just titers have Pad, higher amplifying that can shown longer comments This and as this. potentially neutralization a to We lead other self well the couple

believe of bivalent. I those think And in that will compete the So and we do data the I monovalent tracking we’re positive, seeing our could if Phase booster think I with we that be with think X the are that data trial. some that,

Joseph Payne

would Yes. neutralizing The nature product, dose, and and the the of capability lower broad be… all durability lyophilized extended

Yanan Zhu

Very Yes. Yes. helpful.

the to lung how your in maybe you healthy So remind dosing therapeutic have in healthy I think in if is healthy the a CF patients? dose multiple And about whether program. like couple sufficient is of on volunteers addition blood? is multi-dose the lastly, us in highest potentially data single in and the any the you drug could you wondering, a would volunteer to whether the this dose accumulation volunteers, was dose in or do questions cover study

Pad Chivukula

Pad answer some is this Hi, of I’ll questions. your Yes. and

Phase that the healthy So in did a Xb preclinical plan to dose, therapeutic do dose intend in four dose that patients was part the again single and a we what ascending study saw different that again we when study X we we mentioned levels We So of Phase range dose the were Phase that the went escalation and also dose is study. – levels to right? was chose single which of we Joe single X that, also models. dose, this, volunteer we into and use effective in

range. patients, the replicated be volunteers, we that and should – the we the in the that’s so of in should right the in some if healthy numbers So – see

Yanan Zhu

would still in Got And administration drug that lung? a the understanding we of get to dose some there this single degradation able will be sense is it.

Pad Chivukula

looking if Of right? at course, obviously, I be either cumbersome, distribution obviously lung the will what quite we the sense at Looking we’re doing biopsies be presented PK, mean, the look we if that you going lung that, asking would right? worked But activity the if was – or what a you’re is on won’t companies be at some to do PK, like be going we of you can other mRNA by look – to get for at to that that, data diseases, be we’re looking that’s not, in at.

Yanan Zhu

I’m sorry.

Just referring to LNP a was to I in clarify, accumulation lung.

Pad Chivukula

for understand I way for to biopsy, the the I’m lung, is a asking, doing Yes. but that. doing I what example, sure and it not be you’re mean In we’ll right? look

Yanan Zhu

Right.

Got you. Okay. Thank it. Got it.

Joseph Payne

Thanks, Yanan.

Operator

next Laidlaw & Thank question. is from Please you. Jen ask question Company. The your Yale from

Yale Jen

Thanks have appears also United the believe does benefit that a first given of And vaccine? Thanks. is, CSL, have that the afternoon. something XXX, that this a outside I for monovalent that Good rights taking earlier question the I signed Meiji year, the follow-up. for from of question Japan has the also question. CSL And deal get could My and to would economically? my be – also outside

Joseph Payne

of bivalent the has CSL COVID Correct. the all States. outside obtained collaboration Yes. in to program and United our rights

the States. So I’m sorry, including United

the with and able of both simultaneously. the So the consequently to global concurrently CSL that we Meiji were on opportunity, because transactions going we close license opportunity had

for out both well frankly. the fortunate were all we collaboration three worked And very that parties,

flus. the working with Meiji And player number respect with excited is obviously so and to be we’re world one with flu. in to And number vaccines respect to the Japan, two in CSL

we certainly for in attractive as and the with can very a very two are prominent various have in economics as know, commercialization. bivalent profit opportunity And the COVID and us for on both you the we XX/XX CSL split markets So Arcturus. rely that players monovalent both

Yale Jen

or the the will the XXX you – volunteer is question without next the in you safety in impact? longer that the for Do on the anticipate future able without either the to the to Okay. have long-term do ensure negative patient trial in drug safety. study study healthy done inhale to Great. And that be a any

Joseph Payne

dose, to I’m that… referring multiple that you’re if sure Well, can I confirm

Yale Jen

And… Right.

Joseph Payne

that on our dosing, level, – definitely time – call. not on we’re just our individual our part as more the a increasing volunteer As clear, for dose we like point so details to everyone provide time, is drug. it’s and the of in want period it’s These the strategy at clinical that our implement sitting next the call on conference and some yes, yes, we’ll dose chair. But clinical strategy, in are an inhaling a of we’re four levels chair likely

the So the and the – okay? inhaling while – the increasing chair we drug, increasing just it’s when we’re we they’re – dose, say as saying time

Yale Jen

updates you side remember Okay. last just And maybe sorry, we maybe know I pipeline may thanks. on the one you any that a little data that? more the curious, I’m on last represented and and core [indiscernible] just mentioned a little be color bit

Joseph Payne

you Thanks. question? Thanks. Did ask Okay.

Yale Jen

Yes, I did.

virus far… terms data so hepatitis in our of B Just

Pad Chivukula

The Yes. hepatitis B yes. product,

technology this technology and a presented targeted that because platform that, our and mRNA recently broad be liver modalities is editing can company that modalities. developing areas therapeutic for nanoparticles we this been capabilities to gene therapeutics. is one that our quite we those in So some obviously that that, very in just applied applicable Arcturus we of space arena. feel encapsulates the But multiple gene that’s believe that therapeutic encouraged – of editing And is

Joseph Payne

hepatocytes. ability was has example, hepatitis the presented to is deliver and Paris data another this recently, the is that technology in because LUNAR mRNAs it’s to specifically, B, more for And large well large example very a received for – of our how

field broader than it’s so before. And – a opportunity opens it bit the of little up

Yale Jen

Okay. Great. Thanks all lot on and progresses. a congrats

Joseph Payne

Okay. Thank you.

Operator

Joe. no now to I you. time. this hand further There back questions Thank are a call at will

Joseph Payne

remaining participating everyone. Hey, we’ll any you if the right Good out to on and night. team to questions, our Thanks of there’s course, reach thanks to for everyone, away. call and get back

Operator

joining. now conference Ladies all you ended. for the you. and gentlemen, Thank has Thank

You may all disconnect.

Arcturus Therapeutics (ARCT) 9 May 232023 Q1 Earnings call transcript